Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2016

View Archived Issues

Merck & Co. reports calcitonin gene-related peptide receptor antagonists

Teijin Pharma reports xanthine oxidase inhibitors

HEC Pharm discloses cyclin-dependent kinase inhibitors

Northeastern University has introduced FAAH and MAGL inhibitors

RB launches a Zika Relief Package in response to the global outbreak

FDA issues refusal to file letter regarding Catalyst's NDA for Firdapse

Biotron to test its antiviral compounds for activity against Zika virus

GVN launches Zika Task Force to combat the global Zika outbreak

Eisai and PIQUR enter collaboration agreement to investigate PQR-309 anderibulin combination

Promising preliminary results from T-cell therapy study in hematological cancers

Nanoparticle formulation of AntimiR-21 induces tumor regression in cancer model

Phase I study determines safe dose of lenalidomide in leukemia and lymphoma

Knight Therapeutics supports Medimetriks' acquisition of OPA-15406

Neon Therapeutics licenses peptide-MHC assay technology

FDA grants breakthrough therapy designation for ocrelizumab in primary progressive MS

Interim data suggest potential for RG-101 as backbone therapy for HCV

Helsinn and Mundipharma enter distribution and license agreement for anamorelin in Northern Europe

Aerie reports phase III 12-month safety results for Rhopressa

ImmunoCellular gains access to Stanford's T-cell receptor identification IP

FibroGen presents phase II data for roxadustat in patients with end-stage renal disease

FDA grants priority review to Portola's BLA for andexanet alfa

Kynurenine-3-monooxygenase inhibition as promising new therapeutic strategy for AP-MODS

Takeda's NDS for ixazomib accepted for priority review in Canada

BMS and Dana-Farber Cancer Institute enter immuno-oncology research collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...